New business is being written on visibly better terms than the company's own recent norm, and the mix shift has just beg
The model's full reasoning — Q3 2018 call → NOWe need to determine if management indicates that economic terms of newest business have stepped up meaningfully above company's own recent norm, and that improvement has only begun to flow into reported results because most business in reported numbers was still written at older terms. We need to find evidence in transcript. The question is about "economic terms of the company's newest business" - prices, rates, fees, spreads, contract sizes, durations, profitability. This seems to be about the company's own business transactions. However, the transcript is about a biopharmaceutical company (Agios) with product launches, clinical trials, etc. The "newest business" might refer to product sales, like TIBSOVO launch. But the question specifically asks about "economic terms" like prices, rates, fees, spreads, contract sizes, durations, or profitability at which its most recent deals, orders, contracts, renewals, or transactions are being struck. This is typical for industries like shipping, insurance, etc. But here it's a pharma company. The transcript discusses launch of TIBSOVO, sales, pricing, reimbursement, etc. But does management indicate that the terms of new business (e.g., pricing, duration of therapy) have improved meaningfully above the company's own recent norm? And that improvement is only beginning to flow into reported results? Let's examine the transcript. The company launched TIBSOVO in July 2018. They report net sales of $4.5 million for the first partial quarter. They discuss launch progress, physician awareness, testing rates, payer mix, etc. They also discuss clinical development, but the question is about economic terms of newest business. Possibly the "newest business" is the launch of TIBSOVO, and the "economic terms" could be the pricing, reimbursement, or duration of therapy. But the question asks about "prices, rates, fees, spreads, contract sizes, durations, or profitability" - for a pharma, maybe the price of the drug, or the duration of treatment (which affects revenue per patient). However, the question specifically says "the company's newest business" - meaning the most recent deals, orders, contracts, renewals, or transactions. In the context of a pharma, that could be the sales of TIBSOVO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| CRBG | Corebridge Financial, Inc. | Q4 2022 | 2023-02-22 | B |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| BRKL | Brookline Bancorp, Inc. | Q2 2022 | 2022-07-30 | B+ |
| INVH | Invitation Homes Inc. | Q2 2022 | 2022-07-28 | B+ |
| MTB | M&T Bank Corporation | Q2 2022 | 2022-07-20 | B+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| GNK | Genco Shipping & Trading Limited | Q2 2021 | 2021-08-07 | A |
| ESS | Essex Property Trust, Inc. | Q2 2018 | 2018-08-03 | B+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
CRL · Q2 2022 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management's comments on Safety Assessment pricing and backlog directly address both required elements: they describe current bookings and backlog at "escalating prices" and "meaningful price increases" that are already achieved on real transactions (not targets or future expectations), while noting that the reported Q2 results are still dominated by older 2022 terms and that the stronger pricing is accelerating into H2 and 2023 bookings.
ESS · Q2 2018 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...YES Management describes the loss-to-lease metric rising to 3.
CTO · Q2 2023 → YESThe question is about whether management indicates that the economic terms of the company's newest business have stepped up meaningfully above the company's own recent norm, and that this improvement ...